drugset / Trial / NCT05457946

Study to Evaluate the Immunogenicity and Safety of LBVD(Hexavalent Vaccine), Given to Healthy Infants at Primary Series

NCT05457946

Phase 2/3 Unknown 1438 enrolled LG Chem
RandomizedParallel-groupOpen-labelPrevention

Summary

The purpose of this study is to evaluate immunogenicity and safety of different doses of candidate hexavalent vaccine in comparison to co-administration of Pentavalent vaccine and Poliomyelitis Vaccine (Inactivated) in separate injections at four weeks after completion of three-dose primary series at 6-10-14 weeks of age when administered to healthy infants and thereby to select the optimal dose of candidate vaccine(Stage 1) and to demonstrate lot-to-lot consistency of three lots of LBVD (Stage 2)

Timeline

Start
2023-04-01
Primary completion
2025-09-30
Completion
2025-09-30

Drugs

EvaluationDrugModalityDoseRoute
Comparator Inactivated Polio vaccine (Sabin strains) Vaccine Intramuscular
Subject LBVD Vaccine Intramuscular
Comparator Pentavalent vaccine Vaccine Intramuscular